The earnings call presented a mixed outlook with both achievements and challenges. While there were positive developments in sales growth, partnership expansion, and financial optimization, significant challenges were faced due to supply chain disruptions, margin declines, and decreased net income.

Company Guidance

In the 2025 financial results call, Stratec provided guidance indicating a flat top-line expectation for the year, matching the previous year's figures on a constant currency basis. The company anticipates an adjusted EBIT margin between 10% and 12%, but expects to end towards the lower end of this range due to product mix and ongoing supply chain issues. Despite these challenges, Stratec confirmed a 2.5% sales increase at constant exchange rates, reaching EUR 175.6 million for the first nine months. The adjusted EBIT margin for this period was 7.3%, down from 8.8% the previous year, largely due to a decline in the gross margin from 27.4% to 25.8%. The company also anticipates a notable improvement in earnings dynamics and a better tax rate in Q4, which should result in a full-year tax rate significantly below the previous 26.5%. Additionally, a successful closing of a EUR 125 million syndicated loan was highlighted, enhancing financial flexibility. The company remains focused on cost discipline, inventory management, and executing its development and partnership strategies to support future growth.

New CFO Appointment

Tanja Bucherl has been appointed as the new CFO, bringing a strong financial background and team spirit to the organization.

Positive Sales Growth

Sales increased by 2.5% at constant exchange rate, reaching EUR 175.6 million, despite supply chain disruptions.

Partnership Development

Material progress in the development of partnerships, including a new customer and significant upturn in development activities.

Successful Loan Acquisition

Closed a EUR 125 million syndicated loan to further optimize financing structure and provide flexibility for future development.

STRATEC Biomedical (DE:SBS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:SBS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 26, 2026	2025 (Q4)	- / -	0.97	―	―	―
Nov 07, 2025	2025 (Q3)	0.17 / 0.13	0.05	160.00% (+0.08)	―	―
Aug 19, 2025	2025 (Q2)	- / 0.09	0.29	-68.97% (-0.20)	―	―
May 30, 2025	2025 (Q1)	- / -	0.07	―	―	―
May 19, 2025	2024 (Q4)	- / 0.12	0.07	71.43% (+0.05)	―	―
Oct 25, 2024	2024 (Q3)	0.38 / 0.05	0.47	-89.36% (-0.42)	―	―
Aug 09, 2024	2024 (Q2)	0.33 / 0.29	0.35	-17.14% (-0.06)	―	―
Apr 26, 2024	2024 (Q1)	- / 0.07	0.145	-51.72% (-0.07)	―	―
Mar 28, 2024	2023 (Q4)	- / 0.51	0.37	37.84% (+0.14)	―	―
Oct 27, 2023	2023 (Q3)	- / 0.47	1	-53.00% (-0.53)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DE:SBS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 07, 2025	€20.65	€19.64	-4.89%
Aug 19, 2025	€25.85	€27.00	+4.45%
May 30, 2025	€25.03	€27.57	+10.16%
May 19, 2025	€24.59	€25.27	+2.79%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does STRATEC Biomedical AG (DE:SBS) report earnings?

STRATEC Biomedical AG (DE:SBS) is schdueled to report earning on Mar 26, 2026, Before Open (Confirmed).

What is STRATEC Biomedical AG (DE:SBS) earnings time?

STRATEC Biomedical AG (DE:SBS) earnings time is at Mar 26, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of STRATEC Biomedical AG stock?

The P/E ratio of STRATEC Biomedical is N/A.

What is DE:SBS EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing